Disease progression in patients with virological suppression in response to HAART is associated with the degree of immunological response

被引:61
作者
Moore, DM
Hogg, RS
Chan, K
Tyndall, M
Yip, B
Montaner, JSG
机构
[1] Univ British Columbia, British Columbia Ctr Excellence HIV AIDS, Vancouver, BC V6Z 1Y6, Canada
[2] Univ British Columbia, Dept Hlth Care & Epidemiol, Vancouver, BC V6Z 1Y6, Canada
[3] Univ British Columbia, Fac Med, Dept Med, Vancouver, BC V6Z 1Y6, Canada
关键词
virological response; immunological response; CD4; cells; antiretroviral therapy;
D O I
10.1097/01.aids.0000196180.11293.9a
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: To determine if immunological response is associated with disease progression in patients with virological suppression after initiating HAART. Design: A cohort study of 1084 treatment-naive participants in the British Columbia HIV/AlDS Drug Treatment Program who had achieved viral loads < 500 copies/ml at 3-9 months after initiating triple-drug therapy. Methods: Cox proportional hazards was used to model the association with disease progression of baseline variables, change in CD4 cell counts and CD4 cell count strata at 6 months. Logistic regression analysis was used to examine associations with two definitions of poor immunological response. Results: Patients were followed for a median of 51.4 months. In univariate analyses, increases in CD4 cell counts of < 25 cells/mu l and absolute CD4 cell counts of < 200 cells/mu l were associated with an increased risk of death or new AIDS events. Two mulitivariate models, one including baseline CD4 cell count and change in CD4 cell count from baseline and the other including only absolute CD4 cell counts at 6 months, were found to predict disease progression in this setting. Increases in CD4 cell count of < 25 cells/mu l were associated with increasing age and inversely associated with low baseline CD4 cell counts, high baseline viral loads and good adherence to therapy. CD4 cell counts of < 200 cells/mu l at 6 months were associated with low baseline CD4 cell counts and having AIDS at baseline. Conclusion: Patients with virological suppression are still at risk for HIV disease progression if adequate immunological responses are not achieved. (C) 2006 Lippincott Williams & Wilkins.
引用
收藏
页码:371 / 377
页数:7
相关论文
共 19 条
[1]  
BANGSBERG D, 2005, 11 C RETR OPP INF BO
[2]   Modeling changes in CD4-positive T-lymphocyte counts after the start of highly active antiretroviral therapy and the relation with risk of opportunistic infections -: The Aquitaine Cohort, 1996-1997 [J].
Binquet, C ;
Chêne, G ;
Jacqmin-Gadda, H ;
Journot, V ;
Savès, M ;
Lacoste, D ;
Dabis, F .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 2001, 153 (04) :386-393
[3]   Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease [J].
Cameron, DW ;
Heath-Chiozzi, M ;
Danner, S ;
Cohen, C ;
Kravcik, S ;
Maurath, C ;
Sun, E ;
Henry, D ;
Rode, R ;
Potthoff, A ;
Leonard, J .
LANCET, 1998, 351 (9102) :543-549
[4]  
Chene G, 2003, LANCET, V362, P679, DOI 10.1016/S0140-6736(03)14229-8
[5]   Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy [J].
Grabar, S ;
Le Moing, V ;
Goujard, C ;
Leport, C ;
Kazatchkine, MD ;
Costagliola, D ;
Weiss, L .
ANNALS OF INTERNAL MEDICINE, 2000, 133 (06) :401-410
[6]   A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less [J].
Hammer, SM ;
Squires, KE ;
Hughes, MD ;
Grimes, JM ;
Demeter, LM ;
Currier, JS ;
Eron, JJ ;
Feinberg, JE ;
Balfour, HH ;
Dayton, LR ;
Chodakewitz, JA ;
Fischl, MA .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (11) :725-733
[7]   Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study [J].
Ledergerber, B ;
Egger, M ;
Opravil, M ;
Telenti, A ;
Hirschel, B ;
Battegay, M ;
Vernazza, P ;
Sudre, P ;
Flepp, M ;
Furrer, H ;
Francioli, P ;
Weber, R .
LANCET, 1999, 353 (9156) :863-868
[8]   A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients - The INCAS trial [J].
Montaner, JSG ;
Reiss, P ;
Cooper, D ;
Vella, S ;
Harris, M ;
Conway, B ;
Wainberg, MA ;
Smith, D ;
Robinson, P ;
Hall, D ;
Myers, M ;
Lange, JMA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 279 (12) :930-937
[9]   Virologic, immunologic, and clinical response to highly active antiretroviral therapy: the gender issue revisited [J].
Moore, AL ;
Kirk, O ;
Johnson, AM ;
Katlama, C ;
Blaxhult, A ;
Dietrich, M ;
Colebunders, R ;
Chiesi, A ;
Lungren, JD ;
Phillips, AN .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2003, 32 (04) :452-461
[10]  
MOORE DM, 2005, 14 CAN C HIV AIDS RE